Osteoarthritis Pain Market (Drugs) to Grow at 8.38% CAGR Driven by Emergence of New Treatments to 2020

May 26, 2016, 08:30 ET from ReportsnReports

PUNE, India, May 26, 2016 /PRNewswire/ --

A key trend that will boost osteoarthritis pain drugs market growth is the emergence of new treatments. Cardax, a development stage life sciences company, is developing astaxanthin therapies for osteoarthritis treatment. The therapy is expected to fulfil large unmet medical needs in the market. Moreover, Arthritis Research UK is conducting studies to develop new treatments for osteoarthritis. One such study is the arcOGEN study, where the genes involved in osteoarthritis are being investigated, and early trials of stem-cell research are done to help in cartilage regrowth.

Complete report on osteoarthritis pain drugs market spread across 97 pages, analyzing 4 major companies and providing 67 data exhibits now available at http://www.reportsnreports.com/reports/567363-global-osteoarthritis-pain-market-2016-2020.html

The analysts forecast global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020. According to the 2016 report, a key driver of osteoarthritis pain drugs market growth is the high numbers of unmet medical needs. There are a number of unmet medical needs in this market due to the chronic nature of osteoarthritis and the absence of curative therapies. With drugs such as NSAID's, simple analgesics, corticosteroids, and opioids proving effective for individuals with early-to-mid stages of osteoarthritis pain, the competition in the market is strong. However, these options do not provide adequate pain relief in the late stages of osteoarthritis. Ultimately, effective treatment of osteoarthritis pain requires an improved anti-inflammatory molecule, which gives reason for R&D to develop new drugs with better MOA and minimal adverse effects. Thus, absence of effective and safe long-term treatment for creates numerous opportunities for pharmaceutical companies.

Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The Osteoarthritis Pain Drugs Market is divided into the Following Segments Based on Geography: Americas, APAC and EMEA. Key players in the global osteoarthritis pain drugs market: Abbott Laboratories, Johnson & Johnson, Novartis International, and Pfizer. Other prominent vendors in the market are: AbbVie, Abiogen Pharma, Afferent Pharmaceuticals, Astellas Pharma, BioDelivery Sciences International, CrystalGenomics, Cytori Therapeutics, Daiichi Sankyo, Eli Lilly, Endo Pharmaceuticals Holdings, Horizon Pharma, iCeutica, Iroko Pharmaceuticals, Merck, Nuvo Research, Regeneron Pharmaceuticals, Sanofi, SantoSolve, Techfields Pharma, Winston Pharmaceuticals, Yooyoung Pharmaceutical, and Zynerba Pharmaceuticals. Order a copy of Global Osteoarthritis Pain Drugs Market 2016-2020 report @ http://www.reportsnreports.com/Purchase.aspx?name=567363 .

Further, the osteoarthritis pain drugs market report states that one challenge that could restrict market growth is the consumer's preference for alternate therapies.

Another related report is Global Migraine Drugs Market 2016-2020, the analysts forecast global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020. A key market driver is the unmet needs of migraine sufferers around the world. Prophylactic therapy with improved efficacy and tolerability is one of the most significant unmet needs in individuals suffering from migraine. The US Agency for Healthcare Research and Quality estimated that only about 12% of the adults with migraines take preventive medications. Browse complete report @ http://www.reportsnreports.com/reports/541834-global-migraine-drugs-market-2016-2020.html

Explore other new reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:

Facebook:  https://www.facebook.com/ReportsnReports/

LinkedIn:  https://www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports